MannKind (MNKD) Surges to 52-Week High as Afrezza Approval Approaches

NEW YORK (TheStreet) -- MannKind  (MNKD) surged to a 52-week high on Wednesday on high volume as the impending July 15 date for FDA approval of the company's inhaled insulin drug Afrezza approaches.

Wednesday could mark the first day of significant momentum trading on MannKind with a little more than a month to go before the anticipated approval date.

The stock was up 7.15% to $10.19 at 11:51 a.m. Nearly 15 million shares had changed hands, greater than the average volume of 10,762,800.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Price Chart

MNKD Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind in Free Fall After Changes to Insulin Product, Sales Force